3-咪唑-1-基苯胺 | 112677-67-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-咪唑-1-基苯胺
• 中文别名: 3-(咪唑-1-基)苯胺
• 英文名称: 3-(1H-imidazol-1-yl)aniline
• 英文别名: 3-(imidazol-1-yl)phenylamine；3-imidazol-1-ylaniline
• CAS: 112677-67-5
• 化学式: C₉H₉N₃
• mdl: MFCD09258808
• 分子量: 159.191
• InChiKey: JVKJLZRWXBUBFN-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114 °C
• 沸点：
  373.1±25.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下避光保存，并干燥密封。

反应信息

• 作为反应物：
  描述：

  3-咪唑-1-基苯胺 在 palladium on activated charcoal sodium hydroxide 、 disodium hydrogenphosphate 、 4 A molecular sieve 、 氢气 、 碘 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 60.0h， 生成 N-[(1,3-benzodioxol-5-yl)methyl]-1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetamide
  参考文献：
  名称：

  Design, Synthesis, and Activity of 2-Imidazol-1-ylpyrimidine Derived Inducible Nitric Oxide Synthase Dimerization Inhibitors

  摘要：

  By the screening of a combinatorial library for inhibitors of nitric oxide (NO) formation by the inducible isoform of nitric oxide synthase (iNOS) using a whole-cell assay, 2-(imidazol-1-yl)pyrimidines were identified. Compounds were found to inhibit the dimerization of iNOS monomers, thus preventing the formation of the dimeric, active form of the enzyme. Optimization led to the selection of the potent, selective, and orally available iNOS dimerization inhibitor, 21b, which significantly ameliorated adjuvant-induced arthritis in a rat model. Analysis of the crystal structure of the 21b-iNOS monomer complex provided a rationalization for both the SAR and the mechanism by which 21b blocks the formation of the protein-protein interaction present in the dimeric form of iNOS.

  DOI：

  10.1021/jm061319i
• 作为产物：
  描述：

  间溴硝基苯 在 palladium 10% on activated carbon 、 copper(II) bis(trifluoromethanesulfonate) 1,10-菲罗啉 、 氢气 、 caesium carbonate 、 二苄叉丙酮 作用下， 以 甲醇 、 xylene 为溶剂， 反应 53.0h， 生成 3-咪唑-1-基苯胺
  参考文献：
  名称：

  [EN] PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  [FR] COMPOSES PYRROLO-TRIAZINE ANILINE UTILES EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  具有化学式（I）的化合物，以及其药学上可接受的盐、前药和溶剂化物，可用作激酶抑制剂，其中R1、R2、R3、R4、R5、R6、X和Z如规范中所述。

  公开号：

  WO2003090912A1

文献信息

• [EN] ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE<br/>[FR] COMPOSÉS ARYLE ET HÉTÉROARYLE, LEURS UTILISATIONS THÉRAPEUTIQUES DANS DES CONDITIONS ASSOCIÉES À L'ALTÉRATION DE L'ACTIVITÉ DE LA GALACTOCÉRÉBROSIDASE
  申请人：GAIN THERAPEUTICS SA

  公开号：WO2021105906A1

  公开（公告）日：2021-06-03

  The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

  该申请涉及式(IA)和(IB)的化合物：(IA)和(IB)，以及它们的盐和溶剂化物，其中R1a，R2a，A1，A2，A3，A4，R1b，R2b，B1，B2，B3和G如说明书所述，还包括它们的制备方法、包含同一的药物组合物，以及用于治疗和/或预防例如溶酶体贮积病（如克拉伯病）和α-突触核蛋白opathies（如帕金森病）的用途。
• <scp>l</scp><i>-</i>(<i>−</i>)<i>-</i>Quebrachitol as a Ligand for Selective Copper(0)-Catalyzed N-Arylation of Nitrogen-Containing Heterocycles
  作者：Qifan Zhou、Fangyu Du、Yuanguang Chen、Yang Fu、Wenjiao Sun、Ying Wu、Guoliang Chen

  DOI：10.1021/acs.joc.9b00997

  日期：2019.6.21

  l-(−)-Quebrachitol (QCT) has been found as a ligand of copper powder for selective N-arylation of nitrogen-containing heterocycles with aryl halides. Furthermore, another potential catalytic system (copper powder/QCT/t-BuOK) was successfully adapted to unactivated aryl chlorides.

  已经发现1 -（-）-木糖醇（QCT）作为铜粉的配体，用于含氮杂环与芳基卤化物的选择性N-芳基化。此外，另一种潜在的催化体系（铜粉/ QCT / t- BuOK）已成功地用于未活化的芳基氯化物。
• [EN] METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR LA KINASE RAF
  申请人：ARIAD PHARMA INC

  公开号：WO2013162727A1

  公开（公告）日：2013-10-31

  The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

  该发明揭示了通过给予化合物Formula 1或其药学上可接受的盐、溶剂或水合物来治疗或预防由RAF激酶介导的疾病或症状的方法和组合物，其中变量如本文所定义。
• Theramutein modulators
  申请人：Housey Gerad M.

  公开号：US20100016298A1

  公开（公告）日：2010-01-21

  This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

  这项发明涉及的是抑制或激活内源性蛋白变异形式的试剂以及识别这些变异的新方法。特别感兴趣的是那些由突变基因编码的内源性蛋白变异的抑制剂和激活剂，这些变异通常是在暴露于已知是相应未突变内源性蛋白的抑制剂或激活剂的化学试剂之后出现，或者至少是首次被识别为由此类化学试剂引起的。
• N-coating heterocyclic compounds
  申请人：——

  公开号：US20030176454A1

  公开（公告）日：2003-09-18

  A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a): wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group; M is —(CH 2 )n-, —(CH 2 )n-O—(CH 2 )m-or —(CH 2 )n-NH—(CH 2 )m-, wherein n and m are independently 0, 1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; and the moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.

  公式(I)的化合物：其中A是氢原子，一个可选地取代的、不饱和的、含氮的杂环基团，或者公式(a)的基团：其中R是一个可选地取代的芳香族基团或者一个可选地取代的杂环基团；M是—(CH2)n-, —(CH2)n-O—(CH2)m-或—(CH2)n-NH—(CH2)m-，其中n和m各自为0、1或2；Q是一个可选地取代的环烷基烯基团、一个可选地取代的芳香族基团或者一个可选地取代的二价杂环基团；以及公式(b)的部分：是一个可选地取代的、不饱和的、单环、双环、三环或四环的、含氮的杂环基团，它可以包含作为环成员的额外杂原子，选自由氮、氧和硫原子组成的组，其前药或药用盐。